Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group

Lordick, F. and Lorenzen, S. and Hegewisch-Becker, S. and Folprecht, G. and Woell, E. and Decker, T. and Endlicher, E. and Roethling, N. and Fend, F. and Peschel, C. (2007) Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group. JOURNAL OF CLINICAL ONCOLOGY, 25 (18supp): 4526. ISSN 0732-183X, 1527-7755

Full text not available from this repository.
Item Type: Article
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin I
Depositing User: Petra Gürster
Date Deposited: 30 Oct 2020 09:03
Last Modified: 30 Oct 2020 09:03
URI: https://pred.uni-regensburg.de/id/eprint/32605

Actions (login required)

View Item View Item